Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 938-398-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2017-05-05 to 2017-06-29
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 487 (In vitro Mammalian Cell Micronucleus Test)
- Version / remarks:
- adopted 29 July 2016
- Deviations:
- yes
- Remarks:
- The test design, specifically for the treatment, the recovery phase and harvest time, was slightly modified comparing the current proposal given in the OECD Guideline 487.
- Qualifier:
- according to guideline
- Guideline:
- other: Regulation (EC) No 440/2008 of 30 May 2008: In vitro Mammalian Cell Micronucleus Test, No B.49; No L 193
- Version / remarks:
- Commission Regulation (EC) No 640/2012 of 06 July 2012
- Deviations:
- no
- Principles of method if other than guideline:
- The following alterations from the guidelines were performed:
A series of in-house non-GLP validation experiments was performed to get distinct responses of statistical significance when using the specified positive controls. To achieve such response the test design, specifically for the treatment, the recovery phase and harvest time, was slightly modified comparing the current proposal given in the OECD Guideline 487. - GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- in vitro mammalian cell micronucleus test
Test material
- Reference substance name:
- Reaction mass of 2-[4-[(Hexahydro-2,4,6-trioxo-5-pyrimidyl)azo]phenyl]-6-methylbenzothiazole-7-sulphonic acid, compound with 2,2',2''-nitrilotris[ethanol] (1:1) and Lithium 2-[4-[(hexahydro-2,4,6-trioxopyrimidin-5-yl)azo]phenyl]-6-methylbenzothiazole-7-sulphonate
- EC Number:
- 938-398-1
- Molecular formula:
- C24H28N6O9S2.C18H12LiN5O6S2
- IUPAC Name:
- Reaction mass of 2-[4-[(Hexahydro-2,4,6-trioxo-5-pyrimidyl)azo]phenyl]-6-methylbenzothiazole-7-sulphonic acid, compound with 2,2',2''-nitrilotris[ethanol] (1:1) and Lithium 2-[4-[(hexahydro-2,4,6-trioxopyrimidin-5-yl)azo]phenyl]-6-methylbenzothiazole-7-sulphonate
Constituent 1
- Specific details on test material used for the study:
- Batch no.: 0013479406
Method
Species / strain
- Species / strain / cell type:
- hepatocytes: huamn
- Details on mammalian cell type (if applicable):
- CELLS USED
- Source of cells: Human lymphocytes
- Suitability of cells: Human lymphocytes are the most common cells in the micronucleus test and have been used successfully for a long time in in vitro experiments. They show stable spontaneous micronucleus frequencies at a low level.
- Sex, age and number of blood donors: Experiment I: male donor (27 years old)
Experiment II: male donor (23 years old)
- Whole blood were used: Blood cultures were established by preparing an 11 % mixture of whole blood in medium within 30 hrs after blood collection.
- Metabolic activation:
- with and without
- Metabolic activation system:
- Phenobarbital/β-naphthoflavone induced rat liver S9
- Test concentrations with justification for top dose:
- With regard to the content (87.0 g/100 g) of the test item, 2299 μg/mL were applied as top concentration for treatment of the cultures in the pre-test. Test item concentrations ranging from 14.9 to 2299 μg/mL (with and without S9 mix) were chosen for the evaluation of cytotoxicity.
In the pre-test for toxicity, no precipitation of the test item was observed. Since the cultures fulfilled the requirements for cytogenetic evaluation, this preliminary test was designated Experiment I.
Using a Cytokinesis-block proliferation index (CBPI) as an indicator for toxicity, no cytotoxic effects were observed in Experiment I after 4 hours treatment in the absence and presence of S9 mix. Therefore, 2299 μg/mL were chosen as top treatment concentration for Experiment II. - Vehicle / solvent:
- - Vehicle used: Water
- Justification for choice of vehicle:
The solvent was chosen due to its solubility properties and its relative non-toxicity to the cell cultures.
Controls
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- culture medium with 10.0% deionised water
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- mitomycin C
- other: Demecolcin: without metabolic activation (continuous treatment)
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: culture flasks
DURATION
- Exposure duration
Experiment I:
4 hours (with and without S9-mix)
Eperiment II
4 hours (with S9 mix)
20 hours (without S9 mix)
The cells were prepared 40 hours after start of treatment with the test item
- Fixation time (start of exposure up to fixation or harvest of cells): 40 hrs
Cytokinesis blocker: cytochalasin B
NUMBER OF REPLICATIONS: In each experimental group two parallel cultures were analysed
METHODS OF SLIDE PREPARATION AND STAINING TECHNIQUE USED:
The slides were prepared by dropping the cell suspension in fresh fixative onto a clean microscope slide. The cells were stained with Giemsa.
Fixative agent: ice-cold fixative mixture of methanol and glacial acetic acid (19 parts plus 1 part, respectively)
NUMBER OF CELLS EVALUATED:
At least 1000 binucleate cells per culture were scored for cytogenetic damage on coded slides.
The frequency of micronucleated cells was reported as % micronucleated cells.
CRITERIA FOR MICRONUCLEUS IDENTIFICATION:
The criteria for the evaluation of micronuclei are described in the publication of Countryman and Heddle (1976). The micronuclei have to be stained in the same way as the main nucleus. The area of the micronucleus should not extend the third part of the area of the main nucleus.
DETERMINATION OF CYTOTOXICITY
- Method: To describe a cytotoxic effect the CBPI was determined in 500 cells per culture and cytotoxicity is expressed as % cytostasis. A CBPI of 1 (all cells are mononucleate) is equivalent to 100 % cytostasis.
- Rationale for test conditions:
- The micronucleus assay will be considered acceptable if it meets the following criteria:
a) The rate of micronuclei in the solvent controls falls within the historical laboratory control data range.
b) The rate of micronuclei in the positive controls is statistically significant increased.
c) The quality of the slides must allow the evaluation of a sufficient number of analyzable cells. - Evaluation criteria:
- A test item can be classified as non-clastogenic and non-aneugenic if:
− the number of micronucleated cells in all evaluated dose groups is in the range of the historical laboratory control data and
− no statistically significant or concentration-related increase of the number of micronucleated cells is observed in comparison to the respective solvent control.
A test item can be classified as clastogenic and aneugenic if:
− the number of micronucleated cells is not in the range of the historical laboratory control data and
− either a concentration-related increase in three test groups or a statistically significant increase in the number of micronucleated cells is observed. - Statistics:
- Statistical significance was confirmed by the Chi square test (α < 0.05), using a validated test script of “R”, a language and environment for statistical computing and graphics. Within this test script a statistical analysis was conducted for those values that indicated an increase in the number of cells with micronuclei compared to the concurrent solvent control.
Results and discussion
Test results
- Key result
- Species / strain:
- lymphocytes: human
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: No
- Effects of osmolality: No
- Precipitation: No
NUMBER OF CELLS WITH MICRONUCLEI: Please refer to the summary of results table
HISTORICAL CONTROL DATA
Percentage of micronucleated cells in human lymphocyte cultures (2015-2016)
Aqueous solvents: DMEM/Ham’s F12, Deionised water (10 % v/v) Organic solvents: DMSO (0.5 or 1.0 %), Acetone, Ethanol and THF (0.5 %)
Solvent Control without S9
Micronucleated cells in %
Pulse treatment (4/40)
No. of experiments: 78*
Mean: 0.60
95 % Ctrl limit: 0.08 – 1.12 0
1x SD: 0.26
Min – Max: 0.15 – 1.65
Continuous treatment (20/40)
No. of experiments: 79**
Mean: 0.57
95 % Ctrl limit: 0.12 – 1.03
1x SD: 0.23
Min – Max: 0.05 – 1.35
Solvent Control with S9
Micronucleated cells in %
Pulse treatment (4/40)
No. of experiments: 96*
Mean: 0.62
95 % Ctrl limit: 0.16 – 1.08
1x SD: 0.23
Min – Max: 0.15 – 1.30
Positive Control without S9
Micronucleated cells in %
Pulse treatment (4/40)
MMC
No. of experiments: 78
Mean: 12.48
95 % Ctrl limit: 1.44 – 23.52
1x SD: 5.52
Min – Max: 4.15 – 30.30
Continuous treatment (20/40)
Demecolcin
No. of experiments: 81
Mean: 3.72
95 % Ctrl limit: 1.43 – 6.01
1x SD: 1.15
Min – Max: 2.10 – 7.25
Positive Control with S9
Micronucleated cells in %
Pulse treatment (4/40)
CPA
No. of experiments: 165
Mean: 5.16
95 % Ctrl limit: 0.84 – 9.49
1x SD: 2.16
Min – Max: 2.10 – 11.90
ADDITIONAL INFORMATION ON CYTOTOXICITY:
- Measurement of cytotoxicity used: CBPI
Any other information on results incl. tables
Table 1: Summary of results
Exp.
|
Preparation interval
|
Test item concentration in μg/mL |
Proliferation index CBPI |
Cytostasis in %*
|
Micronucleated cells in %** |
95% Ctrl limit |
Exposure period 4 hrs without S9 mix |
||||||
I |
40 hrs |
Solvent control1 |
2.00 |
|
0.65 |
0.08 - 1.12 |
|
|
Positive control2 |
1.67 |
33.3 |
17.95S |
|
|
|
751 |
2.00 |
0.2 |
0.6 |
|
|
|
1314 |
2.01 |
n.c |
0.6 |
|
|
|
2299 |
2.02 |
n.c. |
0.75 |
|
Exposure period 20 hrs without S9 mix |
||||||
II
|
40 hrs
|
Solvent control1 |
2.02 |
|
0.55 |
0.12 - 1.03 |
|
|
Positive control3 |
1.59 |
42.3 |
4.95S |
1.43 - 6.01 |
|
|
751 |
1.92 |
9.3 |
0.45 |
|
|
|
1314 |
1.95 |
6.9 |
0.45 |
|
|
|
2299 |
1.92 |
9.3 |
0.30 |
|
Exposure period 4 hrs with S9 mix |
||||||
I |
40 hrs |
Solvent control1 |
2.07 |
|
0.90 |
0.16 – 1.08 |
|
|
Positive control4 |
1.91 |
15.0 |
4.00S |
0.84 – 9.49 |
|
|
751# |
2.08 |
n.c. |
1.15 |
|
|
|
1314 |
2.07 |
n.c. |
0.70 |
|
|
|
2299 |
2.06 |
0.8 |
0.45 |
|
II |
40 hrs |
Solvent control1 |
2.17 |
|
0.90 |
0.16 – 1.08 |
|
|
Positive control5 |
1.86 |
26.5 |
12.50S |
0.84 – 9.49 |
|
|
751# |
2.12 |
4.4 |
1.10 |
|
|
|
1314# |
2.08 |
7.6 |
1.13 |
|
|
|
2299# |
2.14 |
2.5 |
0.88 |
|
* For the positive control groups and
the test item treatment groups the values are related to the solvent
controls
** The number of micronucleated cells was determined in a sample of 2000 binucleated cells
# The number of micronucleated cells was determined in a sample of 4000 binucleated cells
SThe number of micronucleated cells is statistically significantly higher than corresponding control values
n.c. Not calculated as the CBPI is equal or higher than the solvent control value
1Deion. water 10.0 % (v/v)
2MMC 0.8 μg/mL
3Demecolcin 100 ng/mL
4CPA 17.5 μg/mL
5CPA 15.0 μg/mL
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.